Abstract Details

Title A Comparison of Headache Assessment via Digital Platform in United States (HeAD-US) and American Migraine Prevalence and Prevention (AMPP) Studies: Baseline Demographics and Headache Characteristics

Topic Headache

Presentation(s) P1 - Poster Session 1 (8:00 AM-9:00 AM)

Poster/Presentation
Number 12-002

Objective To compare the baseline characteristics of the Headache Assessment via a Digital platform in United States (HeAD-US) and the American Migraine Prevalence and Prevention (AMPP) studies.

Background The HeAD-US is a new, ongoing longitudinal cohort study of patients with migraine in US, centered around comprehensive data collection via Migraine Buddy’s platform, a smartphone app. The AMPP, sent mailed questionnaires to a representative US panel.

Design/Methods Both studies used the American Migraine Study/AMPP diagnostic module to assess headache features. Episodic migraine (EM; <15 headache days/month) and chronic migraine (CM; ≥15 headache days/month) cases were identified based on the ICHD criteria. We compare the baseline findings of AMPP and HeAD-US studies, considering demographics, headache features, and disability measured by the Migraine Disability Assessment Scale (MIDAS).

Results

In the AMPP, 65.1% (N=12,043) of sample, and in the HeAD-US, 91.7% (N=5961) of sample met the criteria for migraine based on the ICHD-3 diagnostic criteria. The HeAD-US panel was younger (HeAD-US: 40.8±12.8 vs AMPP: 46.4±13.8, p<0.001), had more women (HeAD-US: 90.3% vs AMPP: 79.9%, p <0.001), and more non-white (HeAD-US: 15.9% vs AMPP: 12.4%, p<0.001). The proportion of persons with migraine who had CM was higher in HeAD-US (HeAD-US: 36%, AMPP: 6.6%, p<0.001). Average Monthly headache day frequency was higher in HeAD-US for EM (HeAD-US, 6.1±3.5; AMPP, 3.0±2.8), but lower for CM (HeAD-US: 20.9±5.4 vs AMPP: 22.1±5.3). Severe disability (Grade-IV) based on MIDAS scores were substantially higher in HeAD-US for both CM (HeAD-US: 93.9% vs AMPP: 67.3%, p<0.001) and EM(HeAD-US: 69.2% vs AMPP: 13.2%, p<0.001). In both studies more women than men experienced severe disability (AMPP: Women=17.4% vs Men=14.1%, p<0.001; HeAD-US: Women=78.4% vs Men=74.4%, p<0.039).

Conclusions The HeAD-US and AMPP are large migraine studies with distinct methods for recruitment and data collection. Not surprisingly, HeAD-US participants have higher rates of CM and headache-related disability.

Authors/Disclosures
Ali Ezzati, MD (University of California, Irvine) PRESENTER	The institution of Dr. Ezzati has received research support from NIA. The institution of Dr. Ezzati has received research support from Alzheimer's Association. The institution of Dr. Ezzati has received research support from Cure Alzheimer's Fund.
Kristina M. Fanning, PhD (MIST Reserach)	The institution of Dr. Fanning has received research support from Abbvie. The institution of Dr. Fanning has received research support from NYC Langone Health . The institution of Dr. Fanning has received research support from Uiversity of SC - Irvine. The institution of Dr. Fanning has received research support from AESARA.
Alexandre Urani (Healint)	Alexandre Urani has received personal compensation for serving as an employee of Aptar Digital Health.
Francois Cadiou, MBA (Healint)	Mr. Cadiou has received personal compensation for serving as an employee of Healint.
Richard B. Lipton, MD, FAAN (Albert Einstein College of Medicine)	Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Allergan/Abbvie. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Amgen. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biohaven. Dr. Lipton has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Eli Lilly. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Lundbeck. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for GlaxoSmithKline. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Teva. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Vedanta. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Grifols. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Pfizer. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Axon. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Satsuma. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cool Tech. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BDSI. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Linpharma. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Axsome. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Clexio. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Shiratronics. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Allergan/Abbvie. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biohaven. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli Lilly. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. Dr. Lipton has or had stock in Biohaven.Dr. Lipton has or had stock in Manistee.Dr. Lipton has or had stock in Axon.Dr. Lipton has or had stock in CoolTech. The institution of Dr. Lipton has received research support from Teva. The institution of Dr. Lipton has received research support from Amgen. The institution of Dr. Lipton has received research support from Allergan/Abbvie. The institution of Dr. Lipton has received research support from Gammacore. The institution of Dr. Lipton has received research support from Axsome. The institution of Dr. Lipton has received research support from Charleston Labs. The institution of Dr. Lipton has received research support from Eli Lilly. The institution of Dr. Lipton has received research support from Satsuma. The institution of Dr. Lipton has received research support from NIH . The institution of Dr. Lipton has received research support from Veterans Administration. Dr. Lipton has received publishing royalties from a publication relating to health care.

��ɫ��

��ɫ��